Korea Investment CORP cut its position in shares of Mylan N.V. (NASDAQ:MYL) by 1.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 90,122 shares of the company’s stock after selling 1,700 shares during the period. Korea Investment CORP’s holdings in Mylan N.V. were worth $2,827,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Meeder Asset Management Inc. boosted its holdings in Mylan N.V. by 76.9% during the third quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock worth $106,000 after buying an additional 1,475 shares in the last quarter. Global X Management Co. LLC boosted its holdings in Mylan N.V. by 59.2% during the second quarter. Global X Management Co. LLC now owns 4,801 shares of the company’s stock worth $186,000 after buying an additional 1,786 shares in the last quarter. Doliver Capital Advisors LP purchased a new stake in Mylan N.V. during the second quarter worth $201,000. Eagle Global Advisors LLC purchased a new stake in Mylan N.V. during the second quarter worth $205,000. Finally, Sheaff Brock Investment Advisors LLC purchased a new stake in Mylan N.V. during the second quarter worth $210,000. 72.01% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts have issued reports on MYL shares. Citigroup Inc. raised shares of Mylan N.V. from a “neutral” rating to a “buy” rating and increased their price objective for the company from $36.00 to $42.00 in a report on Wednesday, August 16th. UBS AG reaffirmed a “buy” rating and set a $46.00 price objective (down from $50.00) on shares of Mylan N.V. in a report on Thursday, August 10th. Mizuho reaffirmed a “buy” rating and set a $37.00 price objective (down from $53.00) on shares of Mylan N.V. in a report on Sunday, August 20th. BMO Capital Markets reaffirmed a “buy” rating and set a $45.00 price objective on shares of Mylan N.V. in a report on Friday, September 29th. Finally, ValuEngine raised shares of Mylan N.V. from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and thirteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $41.21.

ILLEGAL ACTIVITY WARNING: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/mylan-n-v-myl-position-cut-by-korea-investment-corp/1682727.html.

Shares of Mylan N.V. (NASDAQ MYL) opened at $35.72 on Monday. Mylan N.V. has a 12-month low of $29.39 and a 12-month high of $45.87. The stock has a market cap of $19,155.95, a PE ratio of 7.17, a P/E/G ratio of 1.93 and a beta of 1.38. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.84 and a current ratio of 1.35.

Mylan N.V. (NASDAQ:MYL) last released its quarterly earnings data on Wednesday, August 9th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.18 by ($0.08). Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The firm had revenue of $2.96 billion for the quarter, compared to analyst estimates of $3 billion. During the same quarter in the previous year, the business posted $1.16 earnings per share. Mylan N.V.’s revenue for the quarter was up 15.7% on a year-over-year basis. analysts predict that Mylan N.V. will post 4.63 EPS for the current year.

Mylan N.V. Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Institutional Ownership by Quarter for Mylan N.V. (NASDAQ:MYL)

Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.